• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Launches Multi-Year Mission to Save 1 Million Puppies from Canine Parvovirus

    1/17/24 8:30:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email

    Calling all Veterinarians and Pet Lovers - Take the "Defend Puppies. Defeat Parvo." Pledge Today to Save Puppies from Deadly Canine Parvovirus 

    GREENFIELD, Ind., Jan. 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today launched the first-of-its-kind, multi-year campaign to save 1 million puppies from unnecessary death from the highly contagious canine parvovirus (parvo). The Defend Puppies. Defeat Parvo. mission seeks to conquer a virus that, without timely and aggressive care, has a mortality rate as high as 91%1. An estimated 900 dogs are diagnosed with parvo daily2 in the U.S. – mostly unvaccinated puppies. Yet Elanco research revealed only 44% of dog owners know what parvo is, with 20% having no knowledge of the disease.3 With dog owners being the first line of defense in protecting their puppies, there is need for more wide-spread education.

    With the introduction of the Defend Puppies. Defeat Parvo. mission, Elanco aims to increase education about this deadly disease, while increasing veterinarian's access to the first and only U.S. Department of Agriculture (USDA) conditionally approved treatment for parvo – Elanco's Canine Parvovirus Monoclonal Antibody.

    The Defend Puppies. Defeat Parvo. mission strengthens Elanco's ability to reach more puppies, more quickly and includes the following:

    • Newly established Elanco's Defenders Fund offers up to $1 million in rebate incentives from Elanco to veterinarians who purchase the Canine Parvovirus Monoclonal Antibody. This can help veterinarians treat more parvo cases, with the ability to track their rebates via myElanco rewards. 
    • The formation of Parvo Defenders Task Force, made up of like-minded industry leaders and advocates who will champion activities throughout the year to bring awareness to parvo and treatment options. Parvo Defenders Task Force members will also serve as advisors, sharing their insight into pain points associated with diagnosing and treating parvo so, together with Elanco, they can help resolve them. 
    • A grassroots campaign that enlists and empowers dog owners, veterinarians and pet lovers to take the "Defend Puppies. Defeat Parvo." pledge to stop puppies from dying of parvo. This comes with a promise to do their part to save 1 million puppies by 2030 by spreading the word about parvo's signs and symptoms as well as breakthrough treatments that can help put a stop to parvo-related deaths. 

    Notable names already committed to the Parvo Defenders Task Force include: 

    • Organizations such as Mars Veterinary Health, IDEXX, Fear Free, Austin Pets Alive, PAWS Chicago, Fix Long Beach
    • As well as influential veterinarians Dr. Hunter Finn, Dr. Kristin Zersen and Dr. Fred Metzger – strengthening Elanco's ability to reach more puppies more quickly.

    "Parvo doesn't have to be a death sentence. Our innovative treatment for parvovirus can help veterinarians and pet owners alleviate the emotional toll associated with parvo," said Dr. Jennifer Miller, technical veterinarian with Elanco. "Elanco's Canine Parvovirus Monoclonal Antibody is redefining how we treat the disease, but we can't defeat parvo alone. We're calling all veterinarians and dog lovers to join our mission and help us save more dogs, more quickly. Together, we can save 1 million puppies by 2030." 

    Clinical efficacy studies demonstrate that Elanco's Canine Parvovirus Monoclonal Antibody delivers targeted efficacy in stopping parvo by blocking its entry into host cells in a puppy's body through a single, intravenous dose. Results have been highly encouraging. In clinical efficacy studies, zero dogs treated with Elanco's Canine Parvovirus Monoclonal Antibody died, and the Canine Parvovirus Monoclonal Antibody treatment helped shorten the course of parvo, helping these puppies feel better, faster.

    "I'm hoping that the canine parvovirus monoclonal antibody will become the standard of care," said Dr. Fred Metzger, task force member. "If we make it our first line of therapy, I think you could divert cases away from the ER and back to the private practitioner, where we can treat a large number of parvo puppies that are not even being looked at right now. I'm hoping it will free up emergency clinics a little bit more to really handle the cases that need more immediate care. I see no reason why the canine parvovirus monoclonal antibody wouldn't be the standard of care moving forward." 

    For more information about the Elanco Defend Puppies. Defeat Parvo. mission, Elanco's Canine Parvovirus Monoclonal Antibody and to Take the Pledge, click here (DefeatParvo.com).

    I pledge to forever keep puppies safe. I pledge to lead by example, spreading the word about parvo, its symptoms and treatment. I pledge, because I know together, we can save 1 million puppies from parvo by 2030.

    ABOUT ELANCO

    Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at elanco.com.

    ©2024 Elanco or its affiliates. Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

    PM-US-23-2394


    1Sykes, JE. Canine Parvovirus Infections and Other Viral Enteritides. Canine and Feline Infectious Diseases. 2014:141-151

    2Elanco Animal Health. Data on File.

    3Elanco Animal Health. Market Data on File.

    Investor Contact: Katy Grissom (317) 273-9248 [email protected]

    Media Contact: Season Solorio (765) 316-0233 [email protected] 

    Elanco logo (PRNewsfoto/Elanco Animal Health)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-launches-multi-year-mission-to-save-1-million-puppies-from-canine-parvovirus-302036358.html

    SOURCE Elanco Animal Health

    Get the next $ELAN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    12/9/2024$18.00Buy
    UBS
    12/2/2024$14.00Market Perform
    Leerink Partners
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    12/19/2023$17.00Buy
    Jefferies
    12/15/2023$16.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/12/25 5:55:46 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/12/25 5:54:06 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/29/25 4:24:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    SEC Filings

    View All

    SEC Form 144 filed by Elanco Animal Health Incorporated

    144 - Elanco Animal Health Inc (0001739104) (Subject)

    8/11/25 3:58:15 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Elanco Animal Health Incorporated

    10-Q - Elanco Animal Health Inc (0001739104) (Filer)

    8/7/25 9:05:13 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    8/7/25 6:27:18 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/11/25 5:13:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/7/25 4:21:21 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/26/24 5:05:35 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elanco Animal Health upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Elanco Animal Health from Market Perform to Outperform and set a new price target of $18.00

    7/17/25 7:51:30 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by William Blair

    William Blair upgraded Elanco Animal Health from Mkt Perform to Outperform

    6/26/25 7:49:03 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Elanco Animal Health with a new price target

    UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00

    12/9/24 7:40:18 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

    GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

    5/28/25 7:25:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Strengthens Board of Directors with Addition of Stacey Ma

    Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

    11/12/24 8:33:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Animal Health Reports Second Quarter 2025 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported

    8/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

    GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

    7/10/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Reports First Quarter 2025 Results

    Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

    5/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco Animal Health Reports Second Quarter 2025 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported

    8/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs

    The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the worldLaunch to begin immediately with product in market before the end of Q3 2025GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission. This approval by the EU reinforces Zenrelia's status as a highly effective, convenient, and safe once-daily oral JAK inhibitor. Zenrelia's approval represents a signific

    7/24/25 5:42:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

    GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

    7/10/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care